Dysmenorrhea affects up to 90% of menstruating women, with moderate to severe pain impacting 1 in 3 women’s daily function, productivity, and mental health.

Global Market Overview:
-Dysmenorrhea therapeutics market: USD 10.9 billion (2024)
-Primary treatments today include NSAIDs and hormonal contraceptives
-Consumers increasingly seeking natural, non-hormonal, and non-opioid solutions

Unmet Needs:
-Natural, non-invasive options
-Better symptom management without hormonal impact
-Convenient, patient-friendly delivery (e.g. gummies)

Eve’s first pharmaceutical product, Dyspro, is a clinically-informed gummy designed to address these gaps - currently in stability testing ahead of TGA submission.